Preliminary Long-Term Results of Homeopathic Treatment of ...
Transcript of Preliminary Long-Term Results of Homeopathic Treatment of ...
© 2019 by the author. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.
Open Access
OBM Integrative and
Complementary Medicine
Research Article
Preliminary Long-Term Results of Homeopathic Treatment of Atopic Diseases in Adult Patients
Elio Rossi *, Marco Picchi, Marialessandra Panozzo, Linda Nurra
Ambulatorio di omeopatia, Padiglione B, Cittadella della Salute-Ospedale Campo di Marte, 55100
Lucca, Italy; E-Mails: [email protected], [email protected], [email protected],
* Correspondence: Elio Rossi; E-Mail: [email protected]
Academic Editor: Mariella Di Stefano
Special Issue: Experience and activities of the Regional Tuscan Centre for Integrative Medicine
OBM Integrative and Complementary Medicine
2019, volume 4, issue 2
doi:10.21926/obm.icm.1902038
Received: November 01, 2018
Accepted: June 03, 2019
Published: June 20, 2019
Abstract
Background: Since the incidence of allergic diseases and asthma is increasing worldwide,
particularly in Western countries, there is an increasing need to find novel interventions to
treat them. Globally, 300 million people suffer from asthma, 200 to 250 million from food
allergies, 20-25 million from drug allergies, and 400 million from rhinitis.
Aim: To study the effects of homeopathic therapy on adult patients affected by atopic
diseases, who were examined at the Homeopathic Clinic of Lucca (Italy), and monitor the
long-term development of their condition over a period of approximately eight years.
Materials and Methods: An observational longitudinal study was conducted on adult
patients with atopic diseases that were treated at the clinic from 1998 to 2017. In addition, a
long-term study was conducted on a subset of 45/104 adult patients that were examined
from 2006 to 2012, with a follow-up of more than five years. The results were assessed in
relation to the Impact on Daily Living (ORIDL) scale. An evaluation was made during each
patient’s visit, during which the patient described his or her clinical situation, which was
translated into a score by the doctor.
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 2/16
Results: A total of 563 adult patients were monitored. Of them, 202 (35.9%) patients
suffered from atopic dermatitis (AD), 204 (36.2%) from allergic rhinitis (AR), and 157 (27.9%)
from asthma. Among the treated patients, 69.3% showed a moderate to major improvement
(71.1% in case of asthma as the primary disease, 69.8% in AR, and 67.1% in AD). At re-
examination after 5-12 years, a complete remission of the atopic symptoms was observed in
69.5% of the subjects (100% for AD, 59.2% for AR, and 75% for asthma). Adults with more
than one atopic disease on the first examination were recovered completely in 54.3% of the
cases.
Conclusions: The findings seem to confirm that homeopathic therapy can yield positive
results in adults with atopic diseases.
Keywords
Atopic diseases; adult patients; homeopathic treatment; short- and long-term results
1. Introduction
The term "atopy" was introduced in 1923 by Coca and Cooke and originated from the Greek
word άtopıa, meaning "out of place" [1]. Atopy refers to an inherited tendency to produce IgE in
response to small amounts of common environmental antigens. This term was originally limited
only to asthma and allergic rhinitis (AR), but in 1933, its use was extended to include atopic
dermatitis (AD). More recently, the term “allergic march” was introduced to refer to the natural
progression of atopic disorders. This begins with dermatitis and the concomitant sensitization to
food and aeroallergens in early childhood, and then progresses to asthma and AR in later
childhood or adulthood [2].
The prevalence of allergic diseases and asthma is increasing worldwide, particularly in Western
countries. Globally, about 200 to 250 million people suffer from food allergies. According to the
World Health Organization, 300 million people have asthma and based on the rising trends, this
figure is expected to increase to 400 million by 2025 [3]. Over 500 million people are affected by
AR [4], with widely varying country-wise figures (5-40%). It generally develops during late
childhood but is most common in adults between 20 and 40 years of age, after which the
incidence gradually diminishes. In several subjects with hay fever, symptoms decline in mid- and
late adulthood. These symptoms appear in response to grass and tree pollen, indoor allergens
including furry pets, and household dust mites [5]. Most individuals present seasonal symptoms
but around 25% experience perennial symptoms.
Recently, the use of complementary and alternative medicine (CAM) in the treatment of
immunological and allergic conditions has increased. According to the National Center for
Complementary and Integrative Health (NCCIH), the term "complementary and alternative
medicine" refers to medicinal products and practices that are not part of standard medical care. If
a non-mainstream practice is used in combination with conventional medicine, it is termed
as “complementary”. If it is used instead of conventional medicine, it is called “alternative” *6+.
Worldwide, over 200 million people use homeopathic treatment on a regular basis and 29% of
the EU’s population use homeopathic medicine for routine healthcare *7+. In Italy, 21.2% of the
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 3/16
population (+ 6.7% compared to 2012) relies on complementary medicines, of which homeopathy
is the most preferred (76.1%) [8].
A recent survey on the use and adverse effects of CAM was carried out by members of the
American Academy of Allergy, Asthma, & Immunology (AAAAI), who examined patterns of usage
of CAM and reported that 81% of the practitioners that responded to the survey had patients
using CAM treatment instead of conventional therapies [9]. More than 20% of the population of
the United States suffers from atopic disorders such as asthma, AR, and AD, of which over 42%
(both adults and children) have used CAM for treatment of their atopic disorders [10]. The
prevalence of CAM for the treatment of allergic diseases is even higher in certain European
countries [11]. Several different studies in the literature have demonstrated the effectiveness of
homeopathy in AR [12-15], asthma [16-20], and AD [21-27].
1.1 The Homeopathic Clinic, Lucca
The Homeopathic Clinic at Lucca (Italy) was established as a pilot project in 1998 with funding
from the Region of Tuscany. The aim of this project was to investigate whether complementary
medicine (CM) could be included in the public healthcare system [28]. In 2002, a Regional
Reference Centre for homeopathy was established at Lucca [29], and since 2017, the Homeopathic
Clinic of Lucca has acted as the CM Coordination Center for the Local Health Authority Tuscany
North-West [30].
In 2012, we published a study on the long-term progression of atopic diseases in children that
were treated with homeopathy at the Homeopathic Clinic of Lucca and followed up after
approximately eight years (range 5-10 years) [31]. In 2016, we extended the scope of our research
to AR and asthma as well [32]. We treated several patients with atopic diseases in whom the onset
of the disease occurred in adulthood. In early adulthood and middle age, respiratory and skin
manifestations are typically related to occupational exposures, lifestyle, and habits such as
tobacco smoking. Although allergic symptoms tend to decrease and disappear during late
adulthood, some patients develop new-onset allergy or asthma in old age [33]. There is a lack of
information regarding the prevalence and prognosis of atopic diseases in adults.
This study aims to fill that gap by analyzing the short- and long-term outcomes of homeopathic
treatment of atopic diseases in adult patients.
2. Aim of the Study
Our aim was to study the effects of homeopathic therapy on adult patients that were affected
by atopic diseases and examined at the Homeopathic Clinic of Lucca between 1998 and 2017, and
to assess the long-term development of atopic symptoms in subjects with a follow-up after at
least five years from the first homeopathic consultation.
3. Materials and Methods
3.1 Design
This retrospective observational cohort study involved two groups: 1) all the adult patients that
were suffering from atopic diseases and were examined at the Homeopathic Clinic of the Campo
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 4/16
di Marte Hospital of Lucca between 1998 and 2017, and 2) a subset of group 1 having a long-term
follow up.
Inclusion criteria for the first group were adulthood, ongoing atopic diseases, and examination
at the Homeopathic Clinic of Lucca. Inclusion criteria for the second group included a long-term
follow up after ≥ five years from the first homeopathic visit.
The personal and clinical data used for this research were stored and processed electronically
in a database.
3.2 Setting
The homeopathic physicians of the clinic were medical practitioners that had attended a
homeopathy school for at least three years and had over 25 years of experience in homeopathy.
They were registered as experts of homeopathy with the Provincial Medical Council according to
the Tuscan law no. 9/2007 [34] and the related Agreement Protocol of 2015 [35]. The average
waiting time for appointments at the clinic was 1-2 months. A homeopathic examination lasted for
about 30 min and consisted of a detailed interview with the patient, a physical examination, and
the analysis of biological and radiological tests.
3.3 Patients
The patients that were examined at the Homeopathic Clinic from 1998 to 2017 were either
referred by their general practitioner or were self-referred. There were no specific criteria for
admission, and anyone who wished to be treated by homeopathy could request an appointment
(Figure 1).
Figure 1 Recruitment, follow-up, and long-term follow-up analysis of adult patients
with atopic diseases in homeopathic treatment.
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 5/16
The major respiratory allergens affecting the patients included members of the family
Gramineae, dust mites, and certain trees (birch, poplar, and olive). Although subjects with
dermatitis did not usually report food allergies, they did show evidence of food intolerance, mainly
to milk and its derivatives, nightshades (tomatoes), and eggs.
3.4 Diagnosis
The diagnosis of AD was made using the criteria proposed by Williams and colleagues in 1994
[20]. A diagnosis of AD can be made if a patient has presented with itchy skin or the parents report
having observed scratching or rubbing their child during the past twelve months.
Additional indicators for the diagnosis are the presence of three or more of the following
criteria:
1. History of dermal involvement (bends of arms, wrists, knees, and ankles; creases around
the neck, and eyes (and also the cheeks of children <10 years of age)
2. History of asthma or hay fever (or history of atopic disease in a first-degree relative if
the child is <4 years of age)
3. History of dry skin over the past year
4. The onset of signs and symptoms in children <2 years of age (not valid for children <4
years)
5. Clear flexural dermatitis (or dermatitis involving the forehead, cheeks, or the outer
aspect of limbs in children <4 years).
In addition, the diagnosis of AD depends on the exclusion of other conditions, such as allergic
contact dermatitis, cutaneous lymphoma, seborrheic dermatitis, psoriasis, scabies, ichthyosis, and
features of other primary diseases.
AR and asthma are traditionally subdivided into "persistent" and "intermittent". On the basis of
the ARIA guidelines, the patients that showed allergic symptoms for less than four days per week
or four weeks per year were classified in the intermittent group, while the rest were classified in
the persistent group. Based on the severity of disease, the patients were classified into mild and
moderate-severe groups [36].
3.5 Informed Consent
All the patients involved in this study had to sign a privacy disclaimer and informed consent
form for treatment and use of their data for future analysis. All the patients were assigned an
individual identification number to anonymize, collect, and store the data in a database.
3.6 Therapy
The therapeutic approach consisted of a medical visit in which the patient was examined from
physical and mental perspectives in relation to existing conditions as well as clinical history. The
goal was to identify a "constitutional" remedy (simillimum)–a remedy shown to produce
symptoms (including general, particular, intellectual, and emotional symptoms) with the highest
similarity to those of the patient, in a healthy individual (prover). The similarity could be at the
"whole person" level, which takes into account the symptoms and signs of the disease, the
patient’s physical symptoms, as well as the personality, temperament, and genetic predispositions.
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 6/16
In acute conditions, this high level of individualization is not always required because ‘similarity’
must be found at a more specific local level. The consideration of the new or most recent
symptoms for the selection of the remedy helped in matching the remedy to the current acute
picture.
Homeopathic therapy generally consisted of the prescription of a single remedy in
Quinquaginta Millesimal (Q or LM) potencies, starting with Q6 and continuing on a progressive
scale of potencies, from Q6 to Q9, Q12, Q18, Q24, Q30, and sometimes Q60, generally for at least
60 days for each potency [37]. The remedies in centesimal and low potencies (6 to 30 CH) were
used in acute cases. In addition, single doses of high centesimal potencies (200, M, or XM) were
also prescribed after treatment with Q potencies.
During the first examination, patients who were suffering from chronic or recurrent diseases
and were previously treated with conventional drugs were advised to slowly reduce and
eventually discontinue them, following gradual improvement by homeopathic therapy. The
patients with acute illnesses were advised on which homeopathic remedies should be taken, or
were directed to conventional treatment in case of failure of the homeopathic remedies.
We generally used individualized homeopathic treatment, which was managed differently in
acute versus chronic situations. In the case of AD, the topical use of basic moisturizing cream and
Calendula cream was recommended.
3.7 Outcome Parameters
In order to understand the response to homeopathic treatment, we considered adult patients
with at least one follow-up visit. Follow-up examinations were carried out after a minimum of two
months and after 6, 12, and 18 months, and possibly during the 2nd, 3rd, 4th, 5th year, and so on.
Information such as demographic data of the patients; clinical diagnoses according to ICD 10
coding; type, potency, and dosage of the prescribed remedy; prescription strategy; and the
classification of the case as acute, chronic, or recurrent was recorded on paper and included in a
database via the computerized clinical record ‘Win-Computerized Homeopathic Investigation
Program’ (C.H.I.P.) *38+.
The results were assessed in relation to the Impact on Daily Living (ORIDL) scale [39], formerly
called the Glasgow Homeopathic Hospital Outcomes Scale or GHHOS [40]. The ORIDL reference
values defined different degrees of improvement: 0 = no change/unsure; +1 = slight improvement,
no effect on daily living; +2 = moderate improvement, affecting daily living; +3 = major
improvement; +4 = cured/back to normal; -1 = slight deterioration, no effect on daily living; -2 =
moderate deterioration, affecting daily living; -3 = major deterioration; -4 = disastrous
deterioration. Our tables did not include the values of -2, -3, and -4 as no patient response
achieved a score of lower than -1. The scores were assigned during the visit of each patient, during
which the patient described his or her clinical situation, which was translated into a score by the
doctor.
We utilized the following criteria to define the physical seriousness of atopic eczema: (1) Clear:
Normal skin with no signs of active atopic eczema; (2) Mild: Patches of dry skin and sporadic
itching (with presence or absence of small red areas); (3) Moderate: Dry skin areas with recurrent
itching and redness (presence or absence of excoriation, localized thickening, and tightness of the
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 7/16
skin); and (4) Severe: Large areas of dry skin, constant itching, redness (with or without excoriation,
widespread skin thickening, bleeding, oozing, cracking, and pigment alteration) [41].
The condition of patients having asthma and AR was classified as follows: (1) mild intermittent
(episodic), (2) mild persistent, (3) moderate persistent, and (4) severe persistent, wherein the term
‘intermittent’ describes symptoms occurring for <4 days/week for <4 consecutive weeks a year,
while ‘persistent’ describes symptoms occurring for >4 days/week for >4 consecutive weeks a year
[42].
3.8 Long-Term Evaluation
Of the 104 adult patients that were re-evaluated between 2006 and 2012, only 53 patients
(50.9%) could be contacted, although only 46 (44.2%) provided useful information. Forty-six
patients (44.2%) were unreachable because of relocation and/or telephone number change and
12 (11.5%) have not yet been found. Of the 46 patients that responded, 19 (41.3%) were male and
27 (58.7%) were female. The mean age was 37.63 ±16.7, with 23 (50%) aged between 15 and 34
years, 19 (41.3%) between 35 and 64 years, and 4 (8.7%) over 64-years-old.
The patients were asked to return to the clinic for a follow-up evaluation. We gathered the data
through a questionnaire survey conducted during the visit or telephonically and evaluated the
principal atopic disease and the overall pattern of symptoms.
The aim of our questionnaire was to evaluate the development of the principal symptoms, the
overall pattern at re-evaluation, and the development of any diseases that was absent during the
first visit. It should be noted that some patients continued homeopathic treatment in private
clinics in the interim period.
The average long-term follow-up (≥ five years) was 8.2 years (8.1 years for allergic dermatitis,
8.2 years for AR, and 8.2 years for asthma).
3.9 Statistical Analysis
Well-trained personnel at the Homeopathic Clinic performed the entry, screening, encoding,
and analysis of the data. The results were analyzed statistically using the Wilcoxon’s test applied to
matched-pair samples associated with a two-tailed significance test, using the statistical software
package PASW (release 18.1 of SPSS, Statistical Package for Social Sciences).
4. Results
A total of 4,152 patients were consecutively examined at the Homeopathic Clinic of Campo di
Marte Hospital in Lucca from September 1998 to December 2017. Of these, 916 (22.1%) were
patients with atopic diseases, of which 353 (38.5%) were pediatric patients (≤ 14 years) and 563
(61.5%) were adults (≥ 15 years).
Table 1 shows the characteristics of the patients with the atopic disease, as well as the two
subgroups of children and adults. Among these patients, 295 (32.2%) suffered from asthma, 281
(30.7%) from AR, and 340 (37.1%) from AD. The adult subgroup of 563 patients (mean age 38.64
years) represented 61.5% of the atopic patients (compared to 353 or 38.5% children). In the adult
subgroup, we observed asthma in 157 (27.9%) patients, AR in 204 (36.2%) patients, and AD in 202
(35.9%) patients.
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 8/16
Unlike the pediatric subgroup that consisted of 60.6% males, the adult subgroup was largely
represented by females (63.9%). In addition, 84.5% of the adult patients had already used
conventional treatment for the existing disease at the time of the first visit, and only 22.7% were
previously treated with homeopathic remedies.
In adults, no significant correlation was observed between the age and the variables indicated
in Table 1, except for patients with AR who were more numerous in the age group of 15-40 years
(42.4%) than in the ≥ 41-year group (28.3%).
Each patient was examined 1 to 5 times and a total of 261 (46.4%) adult patients underwent at
least one follow-up visit. There were no significant differences between patients with and without
follow-up, in terms of demographic and clinical features.
Table 1 Age-wise characteristics of all atopic patients (sex, previous use of
conventional treatment, previous use of homeopathic treatment, atopic diseases, and
follow up).
0-14 years >15 years Total Follow-up
Number of patients n. (%) n. (%) n. (%) n. (%)
353 38.5 563 61.5 916 100 442 48.3
Sex
Male 214 60.6 203 36.1 417 45.5 205 46.4
Female 139 39.4 360 63.9 499 54.5 237 53.6
Patients who had already used conventional treatment for the existing disease at the time of
the first visit
Yes 282 79.9 476 84.5 758 82.8 371 83.9
Patients who had already used homeopathic treatment for the existing disease at the time of
the first visit
Yes 72 20.1 136 24.2 208 22.7 107 24.2
Atopic diseases
Atopic dermatitis 138 39.1 202 35.9 340 37.1 143 32.4
Allergic rhinitis 77 21.8 204 36.2 281 30.7 145 32.8
Asthma 138 39.1 157 27.9 295 32.2 154 34.8
Table 2 shows the number and percentage of all adult patients with atopic diseases with follow-
up, grouped by diseases and ORIDL score for severity of symptoms.
There were 261 (46.4%) adult patients with follow-up, of which 106 (40.6%) had AR, 79 (30.3%)
had AD, and 76 (29.1%) had asthma. Fifty-four adult patients with asthma (71.1%), 74 with AR
(69.8%), and 53 with AD (67.1%) showed a major improvement (ORIDL = +2 +3) or resolution
(ORIDL = 4) of the disease. A total number of 181 patients (69.3%) showed major improvement or
resolution.
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 9/16
Table 2 Results of homeopathic treatment in 261 adult patients with atopic disorders
at follow-up (1998–2017), as evaluated using ORIDL.
Adult atopic
patients with
follow-up
n. 261/563
(46.4%)
ORIDL 0/-1
No changes
or slight
worsening
(%)
ORIDL +1
Slight
improvement
(%)
ORIDL +2
Moderate
improvement
(%)
ORIDL +3
Major
improvement
(%)
ORIDL +4
Resolution
(%)
ORIDL
+2+3+4
(%)
Asthma
(n. 76)
8 14 16 25 13 54
(10.5) (18.4) (21.1) (32.9) (17.1) (71.1)
Allergic rhinitis
(n. 106)
8 24 25 30 19 74
(7.5) (22.6) (23.6) (28.3) (17.9) (69.8)
Atopic dermatitis
(n. 79)
11 15 13 25 15 53
(13.9) (19) (16.5) (31.6) (19) (67.1)
Total
(n. 261)
27 53 54 80 47 181
(10.4) (20.3) (20.7) (30.7) (18) (69.3)
Table 3 summarizes the long-term development of symptoms in 46 followed-up adult patients
with AD, AR, and asthma. In cases where AD was the main disease, 7/7 (100%) patients showed
complete remission. Out of 27 patients with AR as the main disease, 16 (59.2%) presented
complete remission of symptoms, while seven (25%) exhibited mild/intermittent (episodic)
symptoms, three showed moderate/persistent symptoms, and only one (3.7%) continued to show
severe symptoms. Out of 12 patients with asthma, nine (75%) exhibited complete remission of
symptoms, two (16.7%) presented mild/intermittent (episodic) symptoms, and only one (8.3%)
maintained moderate/persistent symptoms.
Of the 46 patients, 35 (76.1%) had exclusively used homeopathy to treat their atopic symptoms
over time, whereas 11 (23.9%) had used and continued to use conventional treatment when
needed, for example, antihistamines during acute seasonal rhinitis. Out of the 35 patients that
exclusively used homeopathy, 27 (77.1%) believed they had completely resolved the atopic
condition, compared to only five of the 11 (45.5%) that used conventional treatment.
Table 4 presents the patients with different atopic diseases and their progression at long-term
follow-up. Out of 46 patients, 24 (53.3%) had other atopic conditions apart from their primary
complaint: 37% had both asthma and AR, 2.2% had asthma and AD, 10.9% had AR and AD, and 2.2%
had asthma, AR, and AD. Twenty-five out of the 46 patients (54.3%) exhibited complete remission
of all associated diseases.
The most frequently and efficaciously prescribed remedies were Sulfur and Silicea for AD,
Pulsatilla pratensis and Arsenicum iodatum for AR, and Natrum sulfuricum and Arsenicum album
for asthma.
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 10/16
Table 3 Distribution of adult atopic patients by level of severity at first visit and at long-term follow-up (n. 46).
Severity of main symptom (first visit)
Severity of main symptom (at the long-term follow-up visit) Mild intermittent/ sporadic
Mild persistent
Moderate persistent
Severe persistent
Absence/remission
Under homeo treatment
No more treatment
Asthma (n. 12) 2 (16.7%) 0 1 (8.3%) 0 0 9 (75%)
9 (75%) Mild intermittent (episodic)/ sporadic (n. 0)
0 0 0 0 0 0
Mild persistent (n. 2) 0 0 0 0 0 2
Moderate persistent (n. 6) 1 0 1 0 0 4
Severe persistent (n. 4) 1 0 0 0 0 3
Allergic rhinitis (n. 27) 7 (25%) 0 3 (11.1%) 1 (3.7%) 9 (33.3%) 7 (25.9%)
16 (59.2%) Mild intermittent (episodic)/ sporadic (n. 0)
0 0 0 0 0 0
Mild persistent (n. 6) 3 0 0 0 2 1 Moderate persistent (n. 10) 3 0 3 0 1 3 Severe persistent (n. 11) 1 0 0 1 6 3 Dermatitis (n. 7) 0 0 0 0 2 (28.6%) 5 (71.4%)
7 (100%)
Mild intermittent (episodic)/ sporadic (n. 0)
0 0 0 0 0 0
Mild persistent (n. 3) 0 0 0 0 0 3 Moderate persistent (n. 2) 0 0 0 0 1 1 Severe persistent (n. 2) 0 0 0 0 1 1 Total (n. 46) 9 (19.6%) 0 4 (8.7%) 1 (2.2%) 11 (23.9%) 21 (45.6%)
33 (69.5%)
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 11/16
Table 4 Distribution and progression of atopic diseases in adult patients at first visit
and at long-term follow-up (n = 46).
Overall
symptoms
(ante)
n. pts
Overall symptoms (long-term)
Asthma Rhinitis Dermatitis Asthma
and
rhinitis
Asthma
and
dermatitis
Rhinitisand
dermatitis
Asthma,
rhinitis,
and
dermatitis
Remission
n. pts n. pts n. pts n. pts n. pts n. pts n. pts n. pts %
Asthma (n. 7) 2 0 0 0 0 0 0 5 71.4
Rhinitis (n. 10) 0 4 0 0 0 0 0 6 60.0
Dermatitis
(n. 5)
0 1 0 0 0 0 0 4 80.0
Asthma and
rhinitis (n. 17)
0 3 1 2 0 2 0 9 52.9
Asthma and
dermatitis (n. 1)
0 0 1 0 0 0 0 0 0.0
Rhinitis and
dermatitis (n. 5)
0 4 0 0 0 0 0 1 20.0
Asthma,
rhinitis, and
dermatitis (n. 1)
0 1 0 0 0 0 0 0 0.0
Total (n. 46) 2 13 2 2 0 2 0 25 54.3
5. Discussion
As this was a retrospective study reporting only clinical activity, we could not compare the
results with a control group. Thus, it was possible that the results were influenced by the natural
course of atopic disease, although it should be noted that adults do not commonly show
spontaneous cure, and 84.5% of our patients (see Table 1) underwent a lengthy period of
conventional treatment without any success.
In a 2006 study on 79 adults (mean age 57 years) that received only conventional treatment, 68%
reported an ongoing incidence of AD, 53% reported eczema, and 12% complained of severe AD
during the follow up after three years [43]. These results suggest that when atopic diseases persist
during adulthood, it will usually continue for many years. Although complete remission is possible
in adult asthma, remission rates are low and limited to milder cases. Longitudinal studies have
indicated that severe asthma has a poorer prognosis and is associated with an increased likelihood
of permanent lung function impairment, hospitalization, and mortality [44].
In a study performed at 35 Italian healthcare centers, only 304 patients out of 2,760 (12.2%)
with allergic rhinitis that had responded to questionnaires said that the response to conventional
treatment was excellent, while 1027 responded ‘good’ (41.3%), 775 ‘fair’ (31.2%), 359 ‘poor’
(14.5%), and 19 said ‘very bad’ (0.8%). In this study, 340 (13.7%) patients were highly satisfied with
the treatment, 1425 were satisfied (57.3%), 703 were not satisfied (28.3%), and 18 were
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 12/16
extremely dissatisfied (0.7%). The extent of dissatisfaction was significantly higher in patients with
moderate-to-severe AR, compared to patients with mild AR (p<0.0001) [45].
The efficacy of homeopathy needs to be demonstrated with randomized controlled trials to
confirm the results observed in this study.
Social changes over the past few years have made it more difficult to locate patients for long-
term follow up after some time. The exclusive use of mobile phones in several families and the
lack of mobile phone directories in Italy made it difficult to reach some patients.
The present study evaluated patients via a face-to-face or telephonic follow-up after
approximately 7–8 years from the start of homeopathic treatment, in order to understand
whether any improvements from homeopathic treatment were sustainable in the long term.
In previous studies [31 3̧2] we analyzed the outcomes of pediatric patients with AD, who were
treated at the same clinic. The first study focused exclusively on AD and was followed by another
study on all the atopic diseases: AD, AR, and asthma. The second study revealed that 75.8% of the
examined children (67.1% with asthma as the primary disease, 84.2% with rhinitis, and 84.2% with
dermatitis) presented moderate to major improvement. At re-evaluation after 5–10 years,
complete remission of the atopic symptoms was observed in 70.1% of the children: 84.2% with AD,
48.1% with AR, and 71.4% with asthma. Forty percent of the children with two or three
concomitant atopic diseases at first examination had completely recovered.
Based on these positive outcomes, we investigated whether similar results could also be
obtained in adults with atopic diseases, or whether the positive response of pediatric patients was
due to factors such as young age and possibly a healthier diet or reduced pharmacological
intoxication.
The findings of this study confirm that the homeopathic treatment of atopic diseases is
effective in adult patients as well. The rates of success are similar, although slightly lower than
those observed in pediatric patients. In short-term evaluation, major improvement or resolution
was obtained in 69.3% of the adults compared to 75.8% of the children.
More specifically, we observed that the results of all atopic diseases are not the same in adults
and children. Major improvement (ORIDL+2+3+4) was observed in 71.1% of the adults vs. 67.1% of
children with asthma; 69.8% of the adults vs. 84.2% of children with AR; and 67.1% of the adults
vs. 84.2% of children with AD. Therefore, homeopathic treatment of asthma seems to be more
effective in adults than in children, while children with AR and AD seem to respond better to
homeopathic treatment.
In addition, among patients with long-term follow up, those who chose exclusive homeopathic
treatment appeared to show better results, with the resolution of atopic symptoms in 77.1% of
the cases (versus 45.5% in patients that chose conventional treatment). This can be explained by
the fact that patients that obtain good results from homeopathic treatment tend to exclusively
utilize homeopathy, whereas patients that obtain inferior results with homeopathy tend to also
use conventional treatment.
In the long-term assessment of patients that were affected by concomitant atopic diseases, 40%
of the pediatric patients (30 cases) showed complete remission of all associated diseases,
compared to 54.3% of the adult patients (46 cases).
Long-term follow up in adults demonstrated that homeopathic treatment reduced the severity
of symptoms even when AD, AR, and asthma persisted over time, which is in contrast to what
generally occurs with conventional treatment.
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 13/16
These results, if confirmed with randomized controlled trials in a larger sample of patients both
in the acute phase (for example in the case of seasonal pollen allergies) and in the chronic state,
could yield important practical consequences. An integrated treatment model for atopic diseases
could be developed with the systematic use of homeopathic treatment preceding conventional
medicines (antihistamines, cortisones, etc.), limiting their use to only the more severe and acute
cases. Furthermore, homeopathic treatment may also be paired with conventional desensitization
therapy.
6. Conclusions
The results of our study demonstrate that homeopathy has positive therapeutic effects not
only in children suffering from atopic diseases, as shown in previous studies but also in adults.
According to these preliminary data, adult patients treated with homeopathy appeared to
show a more significant reduction in the severity of atopic diseases and even a complete remission
at long-term follow-up, compared to results of conventional treatment that are reported in the
literature.
Acknowledgments
We thank Dr. Laura Cignoni for her English translation and Dr. Mariella Di Stefano for
contributing to the bibliographic research and the revision of the text.
Author Contributions
Research conducted by the authors. Elio Rossi carried out the clinical activities and conceived,
designed, and participated in the research and wrote the article. Marco Picchi participated in the
data analysis, the statistical analysis, and writing the article. Marialessandra Panozzo participated
in the writing and discussion of the article. Linda Nurra took part in the data analysis and writing of
the article.
Competing Interests
There are no conflicts of interest.
Funding
This study was supported by the public health system of the Region of Tuscany (Italy).
References
1. Vocabolario Treccani della lingua italiana. 2019 March. Available from:
http://www.treccani.it/Portale/elements/categoriesItems.jsp?pathFile=/sites/default/BancaD
ati/Vocabolario_online/A/VIT_III_A_009843.xml.
2. Spergel JM. From atopic dermatitis to asthma: The atopic march. Ann Allergy Asthma
Immunol. 2010; 105: 99-106.
3. Pawankar R, Canonica GW, Holgate ST, Lockey RF, Blaiss M. The WAO White Book on Allergy.
2013.
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 14/16
4. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its
impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization,
GA(2)LEN and Allergen). Allergy. 2008; 63: 8-160.
5. Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al.
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs.
J Allergy Clin Immunol. 2012; 130: 1049-1062.
6. National Center for Complementary and Integrative Health (NCCIH). Complementary,
alternative, or integrative health: What’s in a name? July 2018. Available from:
https://nccih.nih.gov/health/integrative-health.
7. HRI Homeopathy around the world. March 2019. Available from: https://www.hri-
research.org/resources/essentialevidence/use-of-homeopathy-across-the-world.
8. Eurispes. 29° Rapporto Italia 2017. March 2019. Available from:
https://eurispes.eu/news/eurispes-rapporto-italia-2017-comunicato-stampa.
9. Knudsen TB, Thomsen SF, Nolte H, Backer V. A population based clinical study of allergic and
non-allergic asthma. J Asthma. 2009; 46: 914.
10. Land MH, Wang J. Complementary and alternative medicine use among allergy practices:
Results of a nationwide survey of allergists. J Allergy Clin Immunol Pract. 2018; 6: 95-98.
11. Kapoor S, Bielory L. Allergic rhinoconjunctivitis: Complementary treatments for the 21st
century. Curr Allergy Asthma Rep. 2009; 9: 121.
12. Reilly DT, Taylor MA, McSharry C, Aitchinson T. Is homoeopatha placebo response? Controlled
trial of homoeopathic potency, with pollen in hayfever as model. Lancet. 1986; 2: 881-886.
13. Ludtke R, Wiesenauer M. A meta-analysis of homeopathic treatment of pollinosis with
Galphimia glauca. Wien Med Wochenschr. 1997; 147: 323-327.
14. Kim LS, Riedlinger JE, Baldwin CM, Hilli L, Khalsa SV, Messer SA, et al. Treatment of seasonal
allergic rhinitis using homeopathic preparation of common allergens in the southwest region
of the US: A randomized, controlled clinical trial. Ann Pharmacother. 2005; 39: 617-624.
15. Goossens M, Laekeman G, Aertgeerts B, Buntinx F. Evaluation of the quality of life after
individualized homeopathic treatment for seasonal allergic rhinitis. A prospective, open, non-
comparative study. Homeopathy. 2009; 98: 11-16.
16. Campbell JH, Taylor MA, Beattie N, McSharry C, Aitchison T, Carter R, et al. Is homoeopathy a
placebo response? A controlled trial of homoeopathic immunotherapy in atopic asthma. Am
Rev Resp Dis. 1990; 141: A24.
17. Castellsagu API. Evolution of 26 cases of bronchial asthma with homoeopathic treatment. Br
Homeopath J. 1992; 81: 173-175.
18. McCarney RW1, Linde K, Lasserson TJ. Homeopathy for chronic asthma. Cochrane Database
Syst Rev. 2004; (1): CD000353.
19. Colin P. Homeopathy and respiratory allergies: A series of 147 cases. Homeopathy. 2006; 95:
68-72.
20. Garcia C. Homeopathy as an alternative for asthma treatment. Int J High Dilution Res. 2011;
10: 201-202.
21. Itamura R, Hosoya R. Homeopathic treatment of Japanese patients with intractable atopic
dermatitis. Homeopathy. 2003; 92: 108-114.
22. Mohan GR. Efficacy of homeopathy in childhood asthmas. Homeopathic Links. 2007; 20: 104-
107.
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 15/16
23. Witt CM, Brinkhaus B, Reinhold T, Roll S, Wegscheider K, Wruck K, et al. A comparative
observational study to assess the effectiveness and costs of individualised homeopathy
compared to conventional treatment in children with atopic dermatitis. An example for whole
system research. Eur J Integr Med. 2008; 1: 22.
24. Adler U, Adler M. Homeopathic Q-potencies for atopic dermatitis. Eur J Integr Med. 2010; 2:
175-176.
25. Shafei HF, AbdelDayem SM, Mohamed NH. Individualized homeopathy in a group of Egyptian
asthmatic children. Homeopathy. 2012; 101: 224-230.
26. Eizayaga JE, Eizayaga JI. Prospective observational study of 42 patients with atopic dermatitis
treated with homeopathic medicines. Homeopathy. 2012; 101: 21-27.
27. Nwabudike LC. Atopic dermatitis and homeopathy. Our Dermatology Online. 2012; 3: 217-220.
28. Rossi E, Di Stefano M, Picchi M, Panozzo MA, Noberasco C, Nurra L, et al. Integration of
homeopathy and complementary medicine in the Italian and Region of Tuscany public health
system, and the experience of the Homeopathic Clinic of the Lucca Hospital. Homeopathy.
2018; 107: 90-98.
29. Region of Tuscany. Action Plan on Non-Conventional Medicine (MnC). Renewal of MnC
Regional Commission. Identification of Regional Reference Center. Allocation of PSR funding
to support MnC. Azione di Piano sulle Medicine non Convenzionali (MnC); 2002 September 12.
Tuscany. Banca dati Atti Regionali.
30. Azienda USL Toscana Nord Ovest. Delibera GRT N. 1224/2016: Recepimento linee di indirizzo
ed individuazione centro di coordinamento aziendale di MC. Deliberazione Del Direttore
Generale N. 617 del; 2017 June 21; Toscana.
31. Rossi E, Bartoli P, Bianchi A, Da Fre M. Homeopathy in paediatric atopic diseases: Long-term
results in children with atopic dermatitis. Homeopathy. 2012; 101: 13-20.
32. Rossi E, Picchi M, Bartoli P, Panozzo MA, Cervino C, Nurra L. Homeopathic therapy in pediatric
atopic diseases: Short and long-term results. Homeopathy. 2016; 105: 217-224.
33. Gillman A, Douglass JA. Asthma in the elderly. Asia Pac Allergy. 2012; 2: 101-108.
34. Tuscany Region. Regional Law of Tuscany no. 9/2007. 2014.
35. Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Province Autonome di
Trento e Bolzano. National Agreement among the State and the Regions and Autonomous
Provinces on the rules for education and practice in complementary medicine by medical
doctors, dentists, pharmacists and veterinarians. 3rd. 2013.
36. Williams HC, Burney PGJ, Pembroke AC, Hay RJ. The UK working party's diagnostic criteria for
atopic dermatitis. III. independent hospital validation. Br J Dermatol. 1994; 131: 406-416.
37. De Schepper L. LM potencies: One of the hidden treasures of the Sixth edition of the Organon.
Br Hom J. 1999; 88: 128-134.
38. Rezzani CM. WinChip: Computerized homeopathic investigation program: A data collection
tool to help the doctor in daily practice and a real instrument to prove and improve
homeopathy. Improving the success of homeopathy 2. developing and demonstrating
effectiveness. London; 1999. p. 32.
39. Reilly D, Stewart W, Mercer SW, Bikker AP, Harrison T. Outcome related to impact on daily
living: Preliminary validation of the ORIDL instrument. BMC Health Serv Res. 2007; 7: 139.
40. Reilly D, Taylor M. The evidence profile. Dev Integr Med Complement Ther Med. 1993; 1: 1-50.
OBM Integrative and Complementary Medicine 2019; 4(2), doi:10.21926/obm.icm.1902038
Page 16/16
41. Lewis-Jones S, Mugglestone MA. Management of atopic eczema in children aged up to 12
years: Summary of NICE guidance. BMJ. 2007; 335: 1263e1264.
42. Jenkinson SG, Peters JI. Pearls from the national institutes of health asthma guidelines. PCCU
Lesson. 2019; 13: 2.
43. Sandström Falk MH, Faergemann J. Atopic dermatitis in adults: Does it disappear with age?
Acta Derm Venereol. 2006; 86: 135-139.
44. Lange P. Prognosis of adult asthma. Monaldi Arch Chest Dis. 1999; 54: 350-352.
45. Frati F, Dell'Albani I, Passalacqua G, Bonini S, Rossi O, Senna G, et al. A survey of clinical
features of allergic rhinitis in adults. Med Sci Monit. 2014; 20: 2151-2156.
Enjoy OBM Integrative and Complementary Medicine by:
1. Submitting a manuscript
2. Joining in volunteer reviewer bank
3. Joining Editorial Board
4. Guest editing a special issue
For more details, please visit:
http://www.lidsen.com/journals/icm
OBM Integrative and Complementary Medicine